Charles Sternberg, Assistant Editor05.07.21
Theranica’s Nerivio therapeutic wearable has been selected as the winner of the “Best New Technology Solution for Pain Management” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,850 nominations from over 17 different countries throughout the world.
“Migraine is the third most prevalent disorder in the world and affects approximately 1 billion people,” said James Johnson, managing director, MedTech Breakthrough. “Nerivio addresses this challenging condition by encompassing the best elements of MedTech solutions, including a true digital health non-invasive treatment approach that deploys an innovative mechanism of action and an accompanying app that controls the device while enabling patients to track and manage their migraines. Congratulations to Theranica for this major advancement and being the winner of our important ‘Best New Technology Solution for Pain Management’ award.”
About Nerivio
Nerivio is a first-line drug-free migraine treatment that is safe, effective, intuitive, and accessible. It deploys remote electrical neuromodulation to activate the body’s native conditioned pain modulation mechanism to treat headache and other symptoms associated with migraine. The treatment is personalized through the Nerivio app, which also includes an interactive migraine diary to track treatment sessions and symptoms. The diary can be shared between patients and their healthcare professionals to improve migraine management.
Randomized controlled trials as well as real-world evidence analyses demonstrate Nerivio’s effectiveness in treating migraine symptoms for patients including chronic and adolescent patients.
“A true advancement in digital health, Nerivio is changing the traditional migraine treatment paradigm and will continue to positively impact patients, by providing pain relief and enabling people get back to life,” said Alon Ironi, CEO and co-founder of Theranica. “Thank you to MedTech Breakthrough for recognizing this important alternative in helping patients control this debilitating condition."
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,850 nominations from over 17 different countries throughout the world.
“Migraine is the third most prevalent disorder in the world and affects approximately 1 billion people,” said James Johnson, managing director, MedTech Breakthrough. “Nerivio addresses this challenging condition by encompassing the best elements of MedTech solutions, including a true digital health non-invasive treatment approach that deploys an innovative mechanism of action and an accompanying app that controls the device while enabling patients to track and manage their migraines. Congratulations to Theranica for this major advancement and being the winner of our important ‘Best New Technology Solution for Pain Management’ award.”
About Nerivio
Nerivio is a first-line drug-free migraine treatment that is safe, effective, intuitive, and accessible. It deploys remote electrical neuromodulation to activate the body’s native conditioned pain modulation mechanism to treat headache and other symptoms associated with migraine. The treatment is personalized through the Nerivio app, which also includes an interactive migraine diary to track treatment sessions and symptoms. The diary can be shared between patients and their healthcare professionals to improve migraine management.
Randomized controlled trials as well as real-world evidence analyses demonstrate Nerivio’s effectiveness in treating migraine symptoms for patients including chronic and adolescent patients.
“A true advancement in digital health, Nerivio is changing the traditional migraine treatment paradigm and will continue to positively impact patients, by providing pain relief and enabling people get back to life,” said Alon Ironi, CEO and co-founder of Theranica. “Thank you to MedTech Breakthrough for recognizing this important alternative in helping patients control this debilitating condition."
